No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Heilongjiang ZBD Pharmaceutical Secures Approval for Chemical Raw Material Drug Listing
ZBD Pharma Gets China Approval for Antibacterial Injection
Heilongjiang ZBD Pharmaceutical Co., Ltd.'s (SHSE:603567) Stock Price Dropped 3.8% Last Week; Private Equity Firms Would Not Be Happy
Report for the third quarter of 2024 of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd.
While Shareholders of Heilongjiang ZBD Pharmaceutical (SHSE:603567) Are in the Red Over the Last Three Years, Underlying Earnings Have Actually Grown
Heilongjiang ZBD Pharmaceutical (SHSE:603567) Is Making Moderate Use Of Debt